Oppositely, introducing a CSF1R inhibitor later on at 10 months of age did not detectably alter Aß load in the same 5xFAD model (Spangenberg et al., 2016) or in 12-month-old APP-PS1 mice [Swedish mutation in APP and humanized PSEN1 (Jankowsky et al., 2004; Radde et al., 2006)] (Unger et al., 2018), emphasizing the differential roles exerted by microglia across AD pathology progression (Casali et al., 2020). This evidence concerns the gene APP and Alzheimer disease.